Evidence map›Paper›PMID 38683990›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

A general approach for selection of epitope-directed binders to proteins.

Jie Zhou, Chau Q Le, Yun Zhang, James A Wells

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jie ZhouDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.
Chau Q LeDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.
Yun ZhangDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.
James A WellsDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.ORCID 0000-0001-8267-5519

Funding

Renewable antibodies to secreted proteins and single and multi-pass cell surfaceP41CA196276 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARKS, JAMES D. · 2014 to 2018
$5.8M
Affinity-directed tagging of protein binding partners in signalingR01CA191018 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WELLS, JAMES A · 2014 to 2018
$1.6M
Regulating Proteolysis to Dissect ApoptosisR01GM097316 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WELLS, JAMES A · 2011 to 2014
$1.1M
Unveiling the Oncogenic Roles of ADAM10/17 by Comprehensively Profiling Proteolytic Activity on a Synthetic Human Protein Peptide Phage LibraryF32CA236151 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZHOU, JIE · 2019 to 2021
$195k
NCI NIH HHS 1P41CA196276NCI NIH HHS 5F32CA236151NCI NIH HHS F32 CA236151NCI NIH HHS P41 CA196276NCI NIH HHS R01 CA191018NIGMS NIH HHS R01 GM097316
6 · The paper itself

Abstract

Directing antibodies to a particular epitope among many possible on a target protein is a significant challenge. Here, we present a simple and general method for epitope-directed selection (EDS) using a differential phage selection strategy. This involves engineering the protein of interest (POI) with the epitope of interest (EOI) mutated using a systematic bioinformatics algorithm to guide the local design of an EOI decoy variant. Using several alternating rounds of negative selection with the EOI decoy variant followed by positive selection on the wild-type POI, we were able to identify highly specific and potent antibodies to five different EOI antigens that bind and functionally block known sites of proteolysis. Among these, we developed highly specific antibodies that target the proteolytic site on the CUB domain containing protein 1 (CDCP1) to prevent its proteolysis allowing us to study the cellular maturation of this event that triggers malignancy. We generated antibodies that recognize the junction between the pro- and catalytic domains for three different matrix metalloproteases (MMPs), MMP1, MMP3, and MMP9, that selectively block activation of each of these enzymes and impair cell migration. We targeted a proteolytic epitope on the cell surface receptor, EPH Receptor A2 (EphA2), that is known to transform it from a tumor suppressor to an oncoprotein. We believe that the EDS method greatly facilitates the generation of antibodies to specific EOIs on a wide range of proteins and enzymes for broad therapeutic and diagnostic applications.

Indexed as

EpitopesAntibodiesHumansMatrix MetalloproteinasesPeptide LibraryProtein BindingProtein EngineeringProteolysisAntibodiesEpitopesMatrix MetalloproteinasesPeptide Librarycancer therapydifferential selectionepitope-directed antibodyphage displayproteolysis

Identifiers

PMID38683990
PMCPMC11087759

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.